{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {},
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Yojana Gadiya",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Multiple sclerosis, a treatable disease.",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "NCIT": "^C\\d+$",
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/0816cb6686751420365441adc6a28ced2d272f14/external/mesh-names.belns"
    },
    "path": "ms/doshi2016.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "61f9799afe61b3137761475e49384221",
      "line": 78,
      "relation": "isA",
      "source": 55,
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "18bfd396ca104da281e76ad754ece076",
      "line": 79,
      "relation": "association",
      "source": 55,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "2c7ad456e19ac1ce858c7667556269fc",
      "line": 80,
      "relation": "association",
      "source": 55,
      "target": 4
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "1d9731c70dd3cedf1f63f58921375110",
      "line": 81,
      "relation": "association",
      "source": 55,
      "target": 88
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "680109bfd2cc214870de113e5cba591a",
      "line": 82,
      "relation": "association",
      "source": 55,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "4d36235b2f8925f4e4768df7da9822dc",
      "line": 83,
      "relation": "association",
      "source": 55,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "6dd290593d43a7ee95e50d2f98230354",
      "line": 91,
      "relation": "association",
      "source": 55,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "409d8ddbbca53e714a7ac4b6dda7ece3",
      "line": 92,
      "relation": "association",
      "source": 55,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "faf4f7562ac7e34a5cb159041ba6af9a",
      "line": 93,
      "relation": "association",
      "source": 55,
      "target": 92
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "de349073f275aeb4565cf8512336d974",
      "line": 172,
      "relation": "positiveCorrelation",
      "source": 55,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "596c113ad7fa3fcb399c4b4506c5a200",
      "line": 173,
      "relation": "positiveCorrelation",
      "source": 55,
      "target": 48
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "1970f0182e27d51a1db4878e7bf8e033",
      "line": 174,
      "relation": "positiveCorrelation",
      "source": 55,
      "target": 89
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "ef7fbe37c89364f1d424e4d5877c6895",
      "line": 79,
      "relation": "association",
      "source": 83,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "cd795d5073cf394dfaf9d7dcefe22c2c",
      "line": 106,
      "relation": "association",
      "source": 83,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "0252a0ee655168a6cf3805fc5e03b8f3",
      "line": 107,
      "relation": "association",
      "source": 83,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "045693516123313a861ac34b837fd579",
      "line": 127,
      "relation": "negativeCorrelation",
      "source": 83,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "3f31436d064c20cee7ea99c053727926",
      "line": 128,
      "relation": "directlyIncreases",
      "source": 83,
      "target": 94
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "a9a4b22bf5e85006347d0252861fe277",
      "line": 80,
      "relation": "association",
      "source": 4,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "6e3e28c3c620a733ffd8f70e98c3619b",
      "line": 81,
      "relation": "association",
      "source": 88,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "d35784fad01f72574eb9ea927b4aedca",
      "line": 82,
      "relation": "association",
      "source": 68,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems.",
      "key": "3d89b85256a618b04d1d1e4a62c4e5cb",
      "line": 83,
      "relation": "association",
      "source": 36,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "98c1644948c652bd282acaee56e792f0",
      "line": 91,
      "relation": "association",
      "source": 59,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "c5aa38bb8d194891e0a6ec651583563b",
      "line": 92,
      "relation": "association",
      "source": 38,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]",
      "key": "dfe08850a676b1f02962808e2a531ebb",
      "line": 93,
      "relation": "association",
      "source": 92,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "CIS encompasses an acute clinical attack affecting one or more CNS sites and can convert to relapsing remitting MS (RRMS).",
      "key": "4e383d08f4ba029e4a7b7ad0d9129de5",
      "line": 99,
      "relation": "negativeCorrelation",
      "source": 42,
      "target": 40
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "CIS encompasses an acute clinical attack affecting one or more CNS sites and can convert to relapsing remitting MS (RRMS).",
      "key": "103d00d2bb754a484e01d31e0aab4919",
      "line": 100,
      "relation": "increases",
      "source": 42,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "70582b939c9d85d969d76a57ee2da2fb",
      "line": 106,
      "relation": "association",
      "source": 42,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "e5521b72a8cdb14a591cde2f9c6b460c",
      "line": 108,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "cytoplasm",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "Brain",
            "namespace": "MESH"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 42,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "CIS encompasses an acute clinical attack affecting one or more CNS sites and can convert to relapsing remitting MS (RRMS).",
      "key": "d83b6149c7c021939c3e2f9ae64df62b",
      "line": 99,
      "relation": "negativeCorrelation",
      "source": 40,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "f947e108d79f14e4d304f3071a01be1d",
      "line": 107,
      "relation": "association",
      "source": 57,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Lymphocytes": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier.",
      "key": "5df09677078eadfcb2fba9618081bcbc",
      "line": 110,
      "relation": "increases",
      "source": 57,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "B-Lymphocytes": true,
          "T-Lymphocytes": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "64a999ddf7f7b68c534c947910a399f5",
      "line": 117,
      "relation": "directlyIncreases",
      "source": 25,
      "target": 91
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "789ed7f25b3b694fc8c41347ec193895",
      "line": 120,
      "relation": "directlyIncreases",
      "source": 25,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "03d906b85166f9cd10a92a802a0f5d78",
      "line": 122,
      "relation": "directlyIncreases",
      "source": 25,
      "target": 60
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "8ed9c61a5054664292086b3a4a383949",
      "line": 124,
      "relation": "directlyIncreases",
      "source": 25,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "771db59fabdfbb1a5cf9d726f5449f36",
      "line": 126,
      "relation": "negativeCorrelation",
      "source": 25,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "B-Lymphocytes": true,
          "T-Lymphocytes": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "49da54260519a6136631fe7bf60e9a26",
      "line": 118,
      "relation": "directlyIncreases",
      "source": 91,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "815a5fd01ebd0c23f0c886e8a4c546fc",
      "line": 121,
      "relation": "directlyIncreases",
      "source": 24,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "d5ce847331af4158cbb16a5084e81500",
      "line": 123,
      "relation": "directlyIncreases",
      "source": 60,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is anterograde and retrograde neurodegeneration with oxidative damage and energy failure.",
      "key": "9f7cf1ef6f799f1b13c50ef23d872f25",
      "line": 163,
      "relation": "increases",
      "source": 60,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is anterograde and retrograde neurodegeneration with oxidative damage and energy failure.",
      "key": "7b741cbfb543ce5d897d4d798a5034b6",
      "line": 164,
      "relation": "increases",
      "source": 60,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "762a45853b5967095ca1be824ce2a319",
      "line": 125,
      "relation": "directlyIncreases",
      "source": 54,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "832ed5836e5bbec87f4be2ea26180d6d",
      "line": 126,
      "relation": "negativeCorrelation",
      "source": 44,
      "target": 25
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the development of the characteristic plaque. [15,16]",
      "key": "7b65891f5a7a1b5c12c40bb4ab396e00",
      "line": 127,
      "relation": "negativeCorrelation",
      "source": 44,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is anterograde and retrograde neurodegeneration with oxidative damage and energy failure.",
      "key": "629da6872af5713488415392d28b7d89",
      "line": 165,
      "relation": "decreases",
      "source": 44,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is anterograde and retrograde neurodegeneration with oxidative damage and energy failure.",
      "key": "0d50fb690481784e31c105df72a90324",
      "line": 166,
      "relation": "decreases",
      "source": 44,
      "target": 34
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Gray Matter": true,
          "White Matter": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying neurodegenerative pathogenesis, but less inflammation. [16,18]",
      "key": "a8e70931a5d589629e29b5c15ba11392",
      "line": 136,
      "relation": "directlyIncreases",
      "source": 56,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Gray Matter": true,
          "White Matter": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying neurodegenerative pathogenesis, but less inflammation. [16,18]",
      "key": "efbe0b7ce47742359261b828c33a6380",
      "line": 137,
      "relation": "directlyIncreases",
      "source": 56,
      "target": 71
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Gray Matter": true,
          "White Matter": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying neurodegenerative pathogenesis, but less inflammation. [16,18]",
      "key": "66102fff5b683afbb3a4a42894468603",
      "line": 138,
      "relation": "increases",
      "source": 56,
      "target": 83
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Gray Matter": true,
          "White Matter": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying neurodegenerative pathogenesis, but less inflammation. [16,18]",
      "key": "60cfc155ce7a52c713300390ef1a6c44",
      "line": 139,
      "relation": "increases",
      "source": 43,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Gray Matter": true,
          "White Matter": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying neurodegenerative pathogenesis, but less inflammation. [16,18]",
      "key": "d6a554bf5d4682ac4b07ac1d658b6d69",
      "line": 140,
      "relation": "increases",
      "source": 71,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The pathological basis appears to be more diffuse brain axonal loss and further microglial activation with atrophy.",
      "key": "cf5af271958630bd235f5dffc527ce1c",
      "line": 158,
      "relation": "directlyIncreases",
      "source": 71,
      "target": 24
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "10–15% of patients have progressive disability from the outset, usually due to spinal cord disease. This is defined as primary progressive MS (PPMS). 1,3,20",
      "key": "8edc09e36c1593a15a139b7b511f323a",
      "line": 146,
      "relation": "directlyIncreases",
      "source": 29,
      "target": 66
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "10–15% of patients have progressive disability from the outset, usually due to spinal cord disease. This is defined as primary progressive MS (PPMS). 1,3,20",
      "key": "4bf9326096e74405e75381a93435b78f",
      "line": 147,
      "relation": "increases",
      "source": 66,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Due to spinal cord dysfunction, patients often have a progressive spastic paraparesis.",
      "key": "6c520ab4a6ad23ac857479b692c4f80c",
      "line": 152,
      "relation": "directlyIncreases",
      "source": 66,
      "target": 62
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The pathological basis appears to be more diffuse brain axonal loss and further microglial activation with atrophy.",
      "key": "4908a7887276146fd34381d15eed2096",
      "line": 157,
      "relation": "directlyIncreases",
      "source": 62,
      "target": 43
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "8c24078075f235479f17f71d397e86ac",
      "line": 172,
      "relation": "positiveCorrelation",
      "source": 45,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "477a306107a65f37887f53344f81d348",
      "line": 173,
      "relation": "positiveCorrelation",
      "source": 48,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]",
      "key": "d32acf4d7539cbcff8cab9473310505c",
      "line": 174,
      "relation": "positiveCorrelation",
      "source": 89,
      "target": 55
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "If the relapse is of moderate functional severity or worse, then high-dose methylprednisolone therapy should be considered, at a dose of 500–1,000 mg per day for 3–5 days as per local guidelines.",
      "key": "df672cd4e0e746355e51412309aeef85",
      "line": 182,
      "relation": "directlyDecreases",
      "source": 0,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "While not disease-modifying, corticosteroids tend to shorten the duration of the relapse.",
      "key": "fc9dee4be130fcc58898b0ef50e861cd",
      "line": 187,
      "relation": "decreases",
      "source": 1,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Plasma exchange is occasionally used, as an adjunctive therapy or alone, if the relapse is rapidly progressive or severe. Therapy interventions, such as physiotherapy, should also be used early to enhance recovery. [4]",
      "key": "b3d66907b0958e58305749ef4d3e2bc7",
      "line": 193,
      "relation": "directlyDecreases",
      "source": 64,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Plasma exchange is occasionally used, as an adjunctive therapy or alone, if the relapse is rapidly progressive or severe. Therapy interventions, such as physiotherapy, should also be used early to enhance recovery. [4]",
      "key": "26a566e3156fdfd7789b7f4503c02fa3",
      "line": 194,
      "relation": "decreases",
      "source": 63,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The most serious side effect occurred unexpectedly about a decade ago with natalizumab – a humanised monoclonal antibody against the cell adhesion molecule alpha 4-integrin – where activation of the John Cunningham virus (JCV) resulted in progressive multifocal leukoencephalopathy (PML).",
      "key": "36ad75bafa362ffdc44485de0601fca9",
      "line": 200,
      "relation": "directlyDecreases",
      "source": 8,
      "target": 26
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The most serious side effect occurred unexpectedly about a decade ago with natalizumab – a humanised monoclonal antibody against the cell adhesion molecule alpha 4-integrin – where activation of the John Cunningham virus (JCV) resulted in progressive multifocal leukoencephalopathy (PML).",
      "key": "36f911674f8a14401b71cb62e895fa96",
      "line": 202,
      "relation": "directlyIncreases",
      "source": 8,
      "target": 49
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "2cbab2f5d49334adc378cec82d309ec6",
      "line": 317,
      "relation": "increases",
      "source": 8,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "9940848c2c67da622e290425edcb603b",
      "line": 318,
      "relation": "increases",
      "source": 8,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "d52ffd5941201d01be9a103f6ca16090",
      "line": 319,
      "relation": "increases",
      "source": 8,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "d348bcf5170b2770a583541a3162078f",
      "line": 320,
      "relation": "increases",
      "source": 8,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The most serious side effect occurred unexpectedly about a decade ago with natalizumab – a humanised monoclonal antibody against the cell adhesion molecule alpha 4-integrin – where activation of the John Cunningham virus (JCV) resulted in progressive multifocal leukoencephalopathy (PML).",
      "key": "bc3b98df893807a3af72208d39ca8a79",
      "line": 201,
      "relation": "isA",
      "source": 26,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "The most serious side effect occurred unexpectedly about a decade ago with natalizumab – a humanised monoclonal antibody against the cell adhesion molecule alpha 4-integrin – where activation of the John Cunningham virus (JCV) resulted in progressive multifocal leukoencephalopathy (PML).",
      "key": "da2876398e0eb8f84c96eed855bbeb74",
      "line": 203,
      "relation": "increases",
      "source": 49,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "PML has also been recently observed, much more rarely, with the oral agents fingolimod and dimethylfumarate. [4,11]",
      "key": "4a59a1ef9ba15b00ddfc443f58b65764",
      "line": 208,
      "relation": "increases",
      "source": 7,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "4c41d7031fca3eae3fccf7db29cfa448",
      "line": 307,
      "relation": "increases",
      "source": 7,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "5a24bc197b1b22caad0f0765dd694ac4",
      "line": 308,
      "relation": "increases",
      "source": 7,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "e43029a718c715ddf32548b001e16249",
      "line": 309,
      "relation": "increases",
      "source": 7,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "8b1af0b3103446eaf16efd9773151b6e",
      "line": 310,
      "relation": "increases",
      "source": 7,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "5e78a2326bfbf064e91ee5cc42754608",
      "line": 311,
      "relation": "increases",
      "source": 7,
      "target": 82
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "88abfd479c5c1a91de1414dde36dbdcd",
      "line": 312,
      "relation": "increases",
      "source": 7,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "6c4c30c064b13898f090b64480443d13",
      "line": 313,
      "relation": "increases",
      "source": 7,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "7d34cfb12176cfda88d89faa29d11eeb",
      "line": 315,
      "relation": "increases",
      "source": 7,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "PML has also been recently observed, much more rarely, with the oral agents fingolimod and dimethylfumarate. [4,11]",
      "key": "82b75665b22ceb265d461abca9c55367",
      "line": 209,
      "relation": "increases",
      "source": 23,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "423e5624f312366427ec81ece8b065d6",
      "line": 299,
      "relation": "increases",
      "source": 23,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "96b9097f07cbb11ef60e88aef34e3438",
      "line": 300,
      "relation": "increases",
      "source": 23,
      "target": 46
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "b20430f8c052f39001fed3f138644cfc",
      "line": 301,
      "relation": "increases",
      "source": 23,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "c02544078cc0529e26a2be90b87c2bf6",
      "line": 302,
      "relation": "increases",
      "source": 23,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "e567a30197345f1be3b43d20797f73fd",
      "line": 303,
      "relation": "increases",
      "source": 23,
      "target": 84
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "d1605abec225e4b560148e48fcb4bbd6",
      "line": 304,
      "relation": "increases",
      "source": 23,
      "target": 87
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "95b13c8b0e8ec83c9b486c1b5a71bed2",
      "line": 305,
      "relation": "increases",
      "source": 23,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "β-interferons and glatiramer acetate are currently the only licensed therapies for CIS in the UK",
      "key": "fddc74883967e2ef3f9ae3475fd14705",
      "line": 215,
      "relation": "decreases",
      "source": 12,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "be5ac164f46b48c0e817c0960253327d",
      "line": 232,
      "relation": "causesNoChange",
      "source": 12,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "β-interferons and glatiramer acetate are currently the only licensed therapies for CIS in the UK",
      "key": "a9b6c96d78612787c3524546214fbff1",
      "line": 216,
      "relation": "decreases",
      "source": 14,
      "target": 42
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "In rapidly progressing SPMS patients, intravenous mitoxantrone can be considered, but this requires close monitoring for cardiac side effects and acute myelogenous leukaemia.",
      "key": "e8b492af9ee735b6693e193593c7a1cb",
      "line": 222,
      "relation": "directlyDecreases",
      "source": 15,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "In rapidly progressing SPMS patients, intravenous mitoxantrone can be considered, but this requires close monitoring for cardiac side effects and acute myelogenous leukaemia.",
      "key": "b2acd4c8f168cdc5df64c8b8004f8448",
      "line": 223,
      "relation": "increases",
      "source": 15,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "In rapidly progressing SPMS patients, intravenous mitoxantrone can be considered, but this requires close monitoring for cardiac side effects and acute myelogenous leukaemia.",
      "key": "15b5678fb490702e6eb5162519db15db",
      "line": 224,
      "relation": "increases",
      "source": 15,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "d3cc33378b5360848368362b1ed79c2e",
      "line": 230,
      "relation": "causesNoChange",
      "source": 13,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "9c6a9776c8bc4aeb2683a5b70bfbbe3e",
      "line": 231,
      "relation": "causesNoChange",
      "source": 21,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "cd3e137a24827dcd36e01e00a617010a",
      "line": 233,
      "relation": "causesNoChange",
      "source": 16,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "dea762cc9c088f0b32f1aa15ef13cd1e",
      "line": 234,
      "relation": "causesNoChange",
      "source": 5,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "93c72469138df69de737fd280f926ae8",
      "line": 235,
      "relation": "causesNoChange",
      "source": 11,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately, the results have essentially been negative. [10]",
      "key": "a72df83f511b10fa0d0f49d3b6da86d3",
      "line": 236,
      "relation": "causesNoChange",
      "source": 3,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "However, the counter to this may be the recently announced groundbreaking results from the ORATORIO trial (NCT01194570, ClinicalTrials.gov) of ocrelizumab – an anti-CD20 depleting molecule – in PPMS and the EXPAND trial (NCT01665144, ClinicalTrials.gov) of siponimod – a selective sphingosine-1-phosphate receptor modulator – in SPMS that delayed the confirmed progression of MS by about 20–25% over 2–3 years [34,35]",
      "key": "7e0c076ee7d8073b4f96d63c8e10cfcd",
      "line": 241,
      "relation": "directlyDecreases",
      "source": 19,
      "target": 27
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "However, the counter to this may be the recently announced groundbreaking results from the ORATORIO trial (NCT01194570, ClinicalTrials.gov) of ocrelizumab – an anti-CD20 depleting molecule – in PPMS and the EXPAND trial (NCT01665144, ClinicalTrials.gov) of siponimod – a selective sphingosine-1-phosphate receptor modulator – in SPMS that delayed the confirmed progression of MS by about 20–25% over 2–3 years [34,35]",
      "key": "8fe48b3c324f6783b76fc41a3866ea6c",
      "line": 242,
      "relation": "decreases",
      "source": 19,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "However, the counter to this may be the recently announced groundbreaking results from the ORATORIO trial (NCT01194570, ClinicalTrials.gov) of ocrelizumab – an anti-CD20 depleting molecule – in PPMS and the EXPAND trial (NCT01665144, ClinicalTrials.gov) of siponimod – a selective sphingosine-1-phosphate receptor modulator – in SPMS that delayed the confirmed progression of MS by about 20–25% over 2–3 years [34,35]",
      "key": "c7030c61bedf822a8b92cf934d7d9530",
      "line": 243,
      "relation": "regulates",
      "source": 17,
      "target": 28
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "However, the counter to this may be the recently announced groundbreaking results from the ORATORIO trial (NCT01194570, ClinicalTrials.gov) of ocrelizumab – an anti-CD20 depleting molecule – in PPMS and the EXPAND trial (NCT01665144, ClinicalTrials.gov) of siponimod – a selective sphingosine-1-phosphate receptor modulator – in SPMS that delayed the confirmed progression of MS by about 20–25% over 2–3 years [34,35]",
      "key": "ef388ea2bd858ed251ad4e3d41a31b14",
      "line": 244,
      "relation": "decreases",
      "source": 17,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "85299a2a85d0115d9e3c29103fcc9d5a",
      "line": 252,
      "relation": "increases",
      "source": 18,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "cddf2b729335c9f9dfb9da8dc459b872",
      "line": 253,
      "relation": "increases",
      "source": 18,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "f251fd5ddcc52206239fef6c53aa2d32",
      "line": 254,
      "relation": "increases",
      "source": 18,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "2d42d55d39d520406793ec11b7d14774",
      "line": 255,
      "relation": "increases",
      "source": 18,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "2c42f9d6f70ffdea55a3cb2224c191cd",
      "line": 256,
      "relation": "increases",
      "source": 18,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "57f0efb8b32566fb918d8f503b4b6c65",
      "line": 257,
      "relation": "increases",
      "source": 18,
      "target": 90
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "0123d4d09ad994597d28d3eb2a7360d9",
      "line": 258,
      "relation": "increases",
      "source": 18,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "7f8484a23b977b101a16d76e89b788bc",
      "line": 259,
      "relation": "increases",
      "source": 18,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "32f7f1197eea37510e3f2123b99d32ef",
      "line": 260,
      "relation": "increases",
      "source": 18,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "e6e7ff982ab08f98aeaa63516fae3c34",
      "line": 262,
      "relation": "increases",
      "source": 10,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "d9dfa3b826365401a20acad0dab34abc",
      "line": 263,
      "relation": "increases",
      "source": 10,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "d3c5ec8ae339c0b530501abc0cfecb23",
      "line": 264,
      "relation": "increases",
      "source": 10,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "8f52205cb006fb5d682a40cfb0e9a1bf",
      "line": 265,
      "relation": "increases",
      "source": 10,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "ac6b18af700fb6ab8cea569e8ad42fb8",
      "line": 266,
      "relation": "increases",
      "source": 10,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "2a406fd02506af796f05ed3f5ca8d45c",
      "line": 267,
      "relation": "increases",
      "source": 10,
      "target": 90
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "910ae125cc2c92af8390f2887dea28f4",
      "line": 268,
      "relation": "increases",
      "source": 10,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "6cc466e83429d0ec20aa2385c40efbdc",
      "line": 269,
      "relation": "increases",
      "source": 10,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "565b0719dc42d9c6a980a3fcd73aa1ab",
      "line": 270,
      "relation": "increases",
      "source": 10,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "b3d0ec535ab79021ee4ce544e7c0f784",
      "line": 271,
      "relation": "increases",
      "source": 10,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "19e5863a95b42e6071a8bcea3b209480",
      "line": 273,
      "relation": "increases",
      "source": 20,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "37a1102a3350c7b4d4f93ff873ff73ee",
      "line": 274,
      "relation": "increases",
      "source": 20,
      "target": 85
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "68fbdde8d7f1288dad42fd446c90c90f",
      "line": 275,
      "relation": "increases",
      "source": 20,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "55c235d86de13ceb714a65dae4197c93",
      "line": 276,
      "relation": "increases",
      "source": 20,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "93c3720d5c25e4e837f0ad56a3afe0e3",
      "line": 277,
      "relation": "increases",
      "source": 20,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "4335b3882ef69238ec1eef849146d82d",
      "line": 278,
      "relation": "increases",
      "source": 20,
      "target": 90
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "43dbbfb3f6e5225cec2892e7015d49d6",
      "line": 279,
      "relation": "increases",
      "source": 20,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "ce9349e1f164a1ac061ecbbdb355f4d0",
      "line": 280,
      "relation": "increases",
      "source": 20,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "9bacf21d788503a67534c6939066151e",
      "line": 281,
      "relation": "increases",
      "source": 20,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "c134f86d2cde7dd35414935807428076",
      "line": 282,
      "relation": "increases",
      "source": 20,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "25ac5deb2101e570663a24d7050916bc",
      "line": 284,
      "relation": "increases",
      "source": 20,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "bd87217b1488ee8e705c6711bdec34f0",
      "line": 287,
      "relation": "increases",
      "source": 20,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "607b93cb0dbbeedc6b6c33bf63211522",
      "line": 289,
      "relation": "increases",
      "source": 20,
      "target": 79
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "8d9a7c68021d6864f83b9e59447740de",
      "line": 290,
      "relation": "increases",
      "source": 20,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "b66fd563c3b25ee1b57c7eb4f6ea78fd",
      "line": 291,
      "relation": "increases",
      "source": 20,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "a931cc83d7dc90720f420acc6788c8c8",
      "line": 292,
      "relation": "increases",
      "source": 20,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "7b9e45870a411a3d0c807ddab8626991",
      "line": 294,
      "relation": "increases",
      "source": 22,
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "0f826a3575eb7ef8fad1d9b781dc3efc",
      "line": 295,
      "relation": "increases",
      "source": 22,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "524c5a6ff88945396110875f901bc6ce",
      "line": 296,
      "relation": "increases",
      "source": 22,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "41ba59fe47f05784ecc849b025497780",
      "line": 324,
      "relation": "increases",
      "source": 9,
      "target": 93
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "c3928b41b9ecdf7705aea8adb99f3004",
      "line": 325,
      "relation": "increases",
      "source": 9,
      "target": 80
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "80edf98ba0d627098464dae8b3e6634c",
      "line": 326,
      "relation": "increases",
      "source": 9,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "f6b73acdde977af61b91e9a3b5c9ebd8",
      "line": 327,
      "relation": "increases",
      "source": 9,
      "target": 78
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "8fa718c45c30f16151b8fb2e3e99ff51",
      "line": 328,
      "relation": "increases",
      "source": 9,
      "target": 86
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "09aa65e89b3eee175b4310d0c8a73b99",
      "line": 329,
      "relation": "increases",
      "source": 9,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "a44f4e181f46c1ba34a8e506b4d9c1f4",
      "line": 330,
      "relation": "increases",
      "source": 9,
      "target": 81
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "9b02227ddd66720430041db3c89182ac",
      "line": 331,
      "relation": "increases",
      "source": 9,
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Chataway J",
          "Doshi A"
        ],
        "date": "2016-12-01",
        "db": "PubMed",
        "db_id": "27956442",
        "db_name": "Multiple sclerosis, a treatable disease.",
        "first": "Doshi A",
        "journal": "Clinical medicine (London, England)",
        "last": "Chataway J",
        "pages": "s53-s59",
        "volume": "16"
      },
      "evidence": "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]",
      "key": "6bed29f301a595dafcead20ca70fa4f2",
      "line": 332,
      "relation": "increases",
      "source": 9,
      "target": 61
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"6-methylprednisolone\")",
      "concept": {
        "name": "6-methylprednisolone",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "eea92dc6c8da43a2ee0230ca7f58d30b"
    },
    {
      "bel": "a(CHEBI:corticosteroid)",
      "concept": {
        "name": "corticosteroid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a468686acdbd9b5763eec60c73e99320"
    },
    {
      "bel": "a(MESH:\"Cell Adhesion Molecules\")",
      "concept": {
        "name": "Cell Adhesion Molecules",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "8f9c2f3217f187cb6562bdccae9c0dc8"
    },
    {
      "bel": "a(MESH:\"Immunologic Factors\")",
      "concept": {
        "name": "Immunologic Factors",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6ed947425923ce7faaa31977621e85ca"
    },
    {
      "bel": "a(MESH:\"Motor Neurons\")",
      "concept": {
        "name": "Motor Neurons",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "6194857fbeb6a65f65a78cf7e6822e39"
    },
    {
      "bel": "a(MESH:Immunoglobulins)",
      "concept": {
        "name": "Immunoglobulins",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "ee83657f1cb91b45697f9647ef2f9149"
    },
    {
      "bel": "a(MESH:Lymphocytes)",
      "concept": {
        "name": "Lymphocytes",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "05994a861f52857ee7dd98e839952695"
    },
    {
      "bel": "a(PUBCHEM:107970)",
      "concept": {
        "name": "107970",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "69a2f60643b06d7fecc8ceef6a18ff0b"
    },
    {
      "bel": "a(PUBCHEM:135314782)",
      "concept": {
        "name": "135314782",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "e6cb2faf400c0ee34f5d8166513bf9de"
    },
    {
      "bel": "a(PUBCHEM:135330159)",
      "concept": {
        "name": "135330159",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "80c053cf1e3d707cb3713755a96479cd"
    },
    {
      "bel": "a(PUBCHEM:172232576)",
      "concept": {
        "name": "172232576",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "68f473a57179cb0db99fe3f67b4a620a"
    },
    {
      "bel": "a(PUBCHEM:20279)",
      "concept": {
        "name": "20279",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "4bd6eaa0dbf6f1cd9225d59c411c882a"
    },
    {
      "bel": "a(PUBCHEM:223370366)",
      "concept": {
        "name": "223370366",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "ca8978b5ac7e24b5bfe27b2fc0ab361a"
    },
    {
      "bel": "a(PUBCHEM:2265)",
      "concept": {
        "name": "2265",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "fee1e263a060bbc104136f994fe6fd87"
    },
    {
      "bel": "a(PUBCHEM:3081884)",
      "concept": {
        "name": "3081884",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "ddbe69bd82a4c59996825ee33db337c8"
    },
    {
      "bel": "a(PUBCHEM:4212)",
      "concept": {
        "name": "4212",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "f31775e4a613bb4b82c90aaf7e04a572"
    },
    {
      "bel": "a(PUBCHEM:44151255)",
      "concept": {
        "name": "44151255",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "bf7fc6519941a1f184778ac731dcc794"
    },
    {
      "bel": "a(PUBCHEM:44599207)",
      "concept": {
        "name": "44599207",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "72b98fffbcd8eeab02e22415403feabe"
    },
    {
      "bel": "a(PUBCHEM:47206399)",
      "concept": {
        "name": "47206399",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "11404c29a322b9c586f67d6ab92e4a29"
    },
    {
      "bel": "a(PUBCHEM:47206937)",
      "concept": {
        "name": "47206937",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "3852b69c25ba778b38510618a998137d"
    },
    {
      "bel": "a(PUBCHEM:50070200)",
      "concept": {
        "name": "50070200",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "6ec62070fe4ca86773777dbe521ba345"
    },
    {
      "bel": "a(PUBCHEM:5284373)",
      "concept": {
        "name": "5284373",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "58e65f474a9a48285d2fa329918b51bf"
    },
    {
      "bel": "a(PUBCHEM:54684141)",
      "concept": {
        "name": "54684141",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "07b337c03ab28dbef0530a6469a93aeb"
    },
    {
      "bel": "a(PUBCHEM:637568)",
      "concept": {
        "name": "637568",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "cfb6e2041ec338daa24a91a45673cf19"
    },
    {
      "bel": "bp(GO:\"microglial cell activation\")",
      "concept": {
        "name": "microglial cell activation",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "3c02f523866973a040dc6bfa5b372b2e"
    },
    {
      "bel": "bp(GO:\"transport across blood-brain barrier\")",
      "concept": {
        "name": "transport across blood-brain barrier",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "14eb785286e562595235f7fef6f35952"
    },
    {
      "bel": "p(HGNC:ITGA4)",
      "concept": {
        "name": "ITGA4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "5dd2353ec77585df3ddc7b475d39e72d"
    },
    {
      "bel": "p(HGNC:MS4A1)",
      "concept": {
        "name": "MS4A1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "ad9ecfa29e4d4968bbe05fc7d9ca9781"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Sphingosine 1-phosphate receptors\")",
      "concept": {
        "name": "Sphingosine 1-phosphate receptors",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "e1d36600ec3ae163d5c1f044a7eae6ee"
    },
    {
      "bel": "path(DOID:\"primary progressive multiple sclerosis\")",
      "concept": {
        "name": "primary progressive multiple sclerosis",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "bc354c4df683e76d8f33dad953c46827"
    },
    {
      "bel": "path(EFO:\"movement disorder\")",
      "concept": {
        "name": "movement disorder",
        "namespace": "EFO"
      },
      "function": "Pathology",
      "id": "1eec50034479c95b7700aad85042e8e1"
    },
    {
      "bel": "path(HP:Lipoatrophy)",
      "concept": {
        "name": "Lipoatrophy",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "720272b57f418217f1821418a471ca47"
    },
    {
      "bel": "path(HP:Palpitations)",
      "concept": {
        "name": "Palpitations",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "6e15b3eeafacc7f9bc481727eb25ada8"
    },
    {
      "bel": "path(MESH:\"Amnesia, Anterograde\")",
      "concept": {
        "name": "Amnesia, Anterograde",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "859f1a141462f7b795fb185adb61bdd6"
    },
    {
      "bel": "path(MESH:\"Amnesia, Retrograde\")",
      "concept": {
        "name": "Amnesia, Retrograde",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "82d4a3068b5e1db02aca9d1064f9bedd"
    },
    {
      "bel": "path(MESH:\"Arrhythmias, Cardiac\")",
      "concept": {
        "name": "Arrhythmias, Cardiac",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "647f560a55382a22c7927c85b80e0dcf"
    },
    {
      "bel": "path(MESH:\"Autonomic Nervous System\")",
      "concept": {
        "name": "Autonomic Nervous System",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3429c2731e521d19176604b0e4613c18"
    },
    {
      "bel": "path(MESH:\"Back Pain\")",
      "concept": {
        "name": "Back Pain",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ca4f3b1105472a1a5649d5c101f86106"
    },
    {
      "bel": "path(MESH:\"Body Temperature Changes\")",
      "concept": {
        "name": "Body Temperature Changes",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6a9fda77d65575f899ce61eddb1ae962"
    },
    {
      "bel": "path(MESH:\"Central Nervous System Diseases\")",
      "concept": {
        "name": "Central Nervous System Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1114043399ecabdf9c223540cf1dade5"
    },
    {
      "bel": "path(MESH:\"Central Nervous System\")",
      "concept": {
        "name": "Central Nervous System",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3ba2ff86fe023cd72cf3b8bb4b906454"
    },
    {
      "bel": "path(MESH:\"Chest Pain\")",
      "concept": {
        "name": "Chest Pain",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6f89f8df7f653c212afd85bf13db4180"
    },
    {
      "bel": "path(MESH:\"Demyelinating Diseases\")",
      "concept": {
        "name": "Demyelinating Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "fd58854d02026d9f5fa3d1ebdeaee004"
    },
    {
      "bel": "path(MESH:\"Diffuse Axonal Injury\")",
      "concept": {
        "name": "Diffuse Axonal Injury",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5c071ab33c311b21362da90fd43f77d1"
    },
    {
      "bel": "path(MESH:\"Energy Metabolism\")",
      "concept": {
        "name": "Energy Metabolism",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "266b2ade166522498effb10b3b6890c9"
    },
    {
      "bel": "path(MESH:\"Epstein-Barr Virus Infections\")",
      "concept": {
        "name": "Epstein-Barr Virus Infections",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "152f451c5e17ac13db8d9a8224992412"
    },
    {
      "bel": "path(MESH:\"Gastrointestinal Diseases\")",
      "concept": {
        "name": "Gastrointestinal Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "65637db6fc27015bacce56a4e46e53f8"
    },
    {
      "bel": "path(MESH:\"Herpes Simplex\")",
      "concept": {
        "name": "Herpes Simplex",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0672e065c1938111ad26cf000e56ce05"
    },
    {
      "bel": "path(MESH:\"Infectious Mononucleosis\")",
      "concept": {
        "name": "Infectious Mononucleosis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "813247bd2ac3cbd728ba4b6afaf3f897"
    },
    {
      "bel": "path(MESH:\"JC Virus\")",
      "concept": {
        "name": "JC Virus",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "8e8df2bc9c9d8c84859a09ccca60434a"
    },
    {
      "bel": "path(MESH:\"Leukemia, Myeloid, Acute\")",
      "concept": {
        "name": "Leukemia, Myeloid, Acute",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "8f8b4f6b77c749b85b557d429e8530b1"
    },
    {
      "bel": "path(MESH:\"Leukoencephalopathy, Progressive Multifocal\")",
      "concept": {
        "name": "Leukoencephalopathy, Progressive Multifocal",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "27dba5ef12814b43b3ec9eca4bb12040"
    },
    {
      "bel": "path(MESH:\"Liver Diseases\")",
      "concept": {
        "name": "Liver Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f9905408f2d14ab23c2a3b5c1b09b869"
    },
    {
      "bel": "path(MESH:\"Macular Edema\")",
      "concept": {
        "name": "Macular Edema",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "80ca6797d3e6c4899bacb3a8a4c4e013"
    },
    {
      "bel": "path(MESH:\"Mitochondrial Diseases\")",
      "concept": {
        "name": "Mitochondrial Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "23abb882b2958f2aad620337f92d6e12"
    },
    {
      "bel": "path(MESH:\"Multiple Sclerosis\")",
      "concept": {
        "name": "Multiple Sclerosis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "075dea8e440aa2624d0899dd5060868e"
    },
    {
      "bel": "path(MESH:\"Multiple Sclerosis, Chronic Progressive\")",
      "concept": {
        "name": "Multiple Sclerosis, Chronic Progressive",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4dc05b53deadbb6dcd241b6d39f0f32a"
    },
    {
      "bel": "path(MESH:\"Multiple Sclerosis, Relapsing-Remitting\")",
      "concept": {
        "name": "Multiple Sclerosis, Relapsing-Remitting",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "1c041f3b0601eb83b8dfbcdcef015e03"
    },
    {
      "bel": "path(MESH:\"Neurodegenerative Diseases\")",
      "concept": {
        "name": "Neurodegenerative Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "c04acd23e7e69b92e4e4230d8551fcf4"
    },
    {
      "bel": "path(MESH:\"Optic Neuritis\")",
      "concept": {
        "name": "Optic Neuritis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "51633e3d9d5c4ddbc39d129fccc58ea2"
    },
    {
      "bel": "path(MESH:\"Oxidative Stress\")",
      "concept": {
        "name": "Oxidative Stress",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5d5071d9dea362c9b9b6ee5de9eb67be"
    },
    {
      "bel": "path(MESH:\"POEMS Syndrome\")",
      "concept": {
        "name": "POEMS Syndrome",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "6a3961c6461222dd965b75d12b369e56"
    },
    {
      "bel": "path(MESH:\"Paraparesis, Spastic\")",
      "concept": {
        "name": "Paraparesis, Spastic",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f22a46e910a98f66da503ae67da9643e"
    },
    {
      "bel": "path(MESH:\"Physical Therapy Modalities\")",
      "concept": {
        "name": "Physical Therapy Modalities",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "530953c1e84ff5be6044bfbda437f2da"
    },
    {
      "bel": "path(MESH:\"Plasma Exchange\")",
      "concept": {
        "name": "Plasma Exchange",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "082841f7e433191653509390c7b4fe6a"
    },
    {
      "bel": "path(MESH:\"Sleep Initiation and Maintenance Disorders\")",
      "concept": {
        "name": "Sleep Initiation and Maintenance Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "0269863fa44919f0f8024eacef024579"
    },
    {
      "bel": "path(MESH:\"Spinal Cord Diseases\")",
      "concept": {
        "name": "Spinal Cord Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3ddae1177c9d56e79263a0d6b2b91b49"
    },
    {
      "bel": "path(MESH:\"Thyroid Diseases\")",
      "concept": {
        "name": "Thyroid Diseases",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "7073d142f7af080d45430f02ae811f97"
    },
    {
      "bel": "path(MESH:\"Visual Perception\")",
      "concept": {
        "name": "Visual Perception",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "44e6b3d2d9b3148faa351a5316606550"
    },
    {
      "bel": "path(MESH:Alopecia)",
      "concept": {
        "name": "Alopecia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "a3f6ab22b2c073151cd3721761fd2f8b"
    },
    {
      "bel": "path(MESH:Anxiety)",
      "concept": {
        "name": "Anxiety",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "81296be1c4ea6bcc3d464a0a9d9342b0"
    },
    {
      "bel": "path(MESH:Atrophy)",
      "concept": {
        "name": "Atrophy",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "7d5394b2784c6e661c25500d859dc266"
    },
    {
      "bel": "path(MESH:Cough)",
      "concept": {
        "name": "Cough",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "9fee4f29ebce7356ac1721785693b80c"
    },
    {
      "bel": "path(MESH:Depression)",
      "concept": {
        "name": "Depression",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "4cbb9f9f3c1f12c3f20dc0eb627a8224"
    },
    {
      "bel": "path(MESH:Diarrhea)",
      "concept": {
        "name": "Diarrhea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "380392a07df61a122a0053ada328efb8"
    },
    {
      "bel": "path(MESH:Dizziness)",
      "concept": {
        "name": "Dizziness",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "7fcdbe633fe55f59d8bf337c0f4df007"
    },
    {
      "bel": "path(MESH:Dyspnea)",
      "concept": {
        "name": "Dyspnea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "3f78d64501d3d9478ac9ad623a28ec72"
    },
    {
      "bel": "path(MESH:Exanthema)",
      "concept": {
        "name": "Exanthema",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2053d43dd947eb0711e442223fdf8ab6"
    },
    {
      "bel": "path(MESH:Fever)",
      "concept": {
        "name": "Fever",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ffc74da80b64d7057f4eff0e06cdd1b6"
    },
    {
      "bel": "path(MESH:Flushing)",
      "concept": {
        "name": "Flushing",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "07c4f43b0f8c387ce6814f806edd8263"
    },
    {
      "bel": "path(MESH:Headache)",
      "concept": {
        "name": "Headache",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2a9db847bd9248b92260deeecc169912"
    },
    {
      "bel": "path(MESH:Hypotension)",
      "concept": {
        "name": "Hypotension",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "39522b7da203af332ad63949d9b8ca3f"
    },
    {
      "bel": "path(MESH:Infection)",
      "concept": {
        "name": "Infection",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "572a317d84677724217aff971083c770"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "concept": {
        "name": "Inflammation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "10cd96fd4056a5e6c27264e0130e89f9"
    },
    {
      "bel": "path(MESH:Ketosis)",
      "concept": {
        "name": "Ketosis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "94e6daf3bcf57b261ae7b454d787d23f"
    },
    {
      "bel": "path(MESH:Lymphopenia)",
      "concept": {
        "name": "Lymphopenia",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "5409b4ca69266591bf641701b8b404c3"
    },
    {
      "bel": "path(MESH:Nausea)",
      "concept": {
        "name": "Nausea",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "41e2b9e6454d4c63a3654236ce97040f"
    },
    {
      "bel": "path(MESH:Proteinuria)",
      "concept": {
        "name": "Proteinuria",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "c390c8f7b1277f17f6325dbefbb54d90"
    },
    {
      "bel": "path(MESH:Sensation)",
      "concept": {
        "name": "Sensation",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "166f200d643d7f032e018c7bacb3fcda"
    },
    {
      "bel": "path(MESH:Smoking)",
      "concept": {
        "name": "Smoking",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "421977e25516b65692cc5c7ed794a7eb"
    },
    {
      "bel": "path(MESH:Vomiting)",
      "concept": {
        "name": "Vomiting",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "364ae88ab20bb2e8a9fd696110a8f558"
    },
    {
      "bel": "path(NCIT:C20613)",
      "concept": {
        "name": "C20613",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "ccb89ba29a2fbf3dc521c1e4fd17e9d5"
    },
    {
      "bel": "path(NCIT:C28314)",
      "concept": {
        "name": "C28314",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "f57edffc4fe7b97d79aaf0597e7833a7"
    },
    {
      "bel": "path(NCIT:C78251)",
      "concept": {
        "name": "C78251",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "ef911aec9fe8a24f92ffdf338cc14571"
    },
    {
      "bel": "path(NCIT:C95603)",
      "concept": {
        "name": "C95603",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "2299d06d09c75e450dca87c044258295"
    }
  ]
}